Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHA:688336)

China · Delayed Price · Currency is CNY

47.65

-0.96 (-1.97%)

Aug 21, 2026, 3:00 PM CST

28.35% (1Y)

Market Cap	42.71B +28.6%
Revenue (ttm)	4.42B +257.0%
Net Income	3.08B +302.4%
EPS	3.40 +297.1%
Shares Out	896.23M
PE Ratio	14.02
Forward PE	66.43
Dividend	0.33 (0.69%)
Ex-Dividend Date	Jun 18, 2026

Volume	16,853,805
Open	48.01
Previous Close	48.61
Day's Range	45.68 - 50.80
52-Week Range	32.26 - 66.62
Beta	0.34
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 21, 2026

About SHA:688336

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs. Its products include Enbrel, a recombinant human type II tumor necrosis factor receptor-antibody fusion protein for the treatment of autoimmune rheumatism and immunology; Jiannipa, a recombinant anti-CD25 humanized monoclonal antibody injection to prevent acute rejection caused by kidney transplantation; and Enbrel, an anti-IL-17A humanized monoclonal antibody ambroxol injection for t... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2002

Employees 1,012

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 688336

Full Company Profile

Financial Performance

In 2025, SHA:688336's revenue was 4.20 billion, an increase of 251.81% compared to the previous year's 1.19 billion. Earnings were 2.90 billion, an increase of 311.49%.

Financial Statements